Sacubitril/valsartan cardioprotective effect against cisplatin-induced cardiotoxicity via modulation of VEGF/eNOS and TLR4/TNFα/IL6 signalling pathways
Journal of Pharmacy and Pharmacology · 2023
DOI: 10.1093/jpp/rgad049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2023. Verfasst von Marwa Monier Mahmoud Refaie und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Minia University, El-Minia, Egypt. Hauptthemen laut MEDLINE: Cardiotoxicity, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Objectives
Drug-induced cardiac injury is a potentially preventable cause of heart failure. Cisplatin (CIS) is a widely used chemotherapeutic agent complicated with cardiotoxicity that limits its clinical application so we aimed to evaluate the suspected cardioprotective effect of sacubitril/valsartan (Sac/Val) against CIS cardiotoxic injury.
Methods
Forty male rats of Wistar albino species were divided into four groups. group I received the vehicle; group II was given the vehicle plus CIS (10 mg/kg) single i.p. on fifth day; group III was given Sac/Val (30 mg/kg/d) orally for 7 days plus CIS (10 mg/kg) single i.p. on fif5th day; group IV was given the same as group III plus nitro-ω-L-arginine (L-NNA) (25 mg/kg/d) orally for 7 days. Key findings CIS-induced cardiotoxicity and L-NNA co-administered group showed significant increases in cardiac enzymes, toxic histopathological features, elevated heart weights, angiotensin II (Ang II), neprilysin, malondialdehyde (MDA), inflammatory mediators, blood pressure (BP) and caspase 3 expressions, but there are significant decreases in the antioxidant parameters, vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS). However, the co-administration of Sac/Val could ameliorate these changes of CIS.
Conclusion
Sac/Val has an important cardioprotective effect against CIS cardiotoxicity with the involvement of eNOS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Medicine, Minia University, El-Minia, Egypt.
- Department of Histology and Cell Biology, Faculty of Medicine, Minia University, El-Minia, Egypt.
- Department of Biochemistry, Faculty of Pharmacy, Minia University, El-Minia, Egypt.
- Department of Cardiology, Faculty of Medicine, Minia University, El-Minia, Egypt.
ORCID-Profile: Marwa Monier Mahmoud Refaie, Rehab Ahmed Rifaai
Zitieren
APA
Mahmoud Refaie, M. M., Ahmed Rifaai, R., Bayoumi, A. M. A., & Shehata, S. (2023). Sacubitril/valsartan cardioprotective effect against cisplatin-induced cardiotoxicity via modulation of VEGF/eNOS and TLR4/TNFα/IL6 signalling pathways. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgad049
Vancouver
Mahmoud Refaie MM, Ahmed Rifaai R, Bayoumi AMA, Shehata S. Sacubitril/valsartan cardioprotective effect against cisplatin-induced cardiotoxicity via modulation of VEGF/eNOS and TLR4/TNFα/IL6 signalling pathways. Journal of Pharmacy and Pharmacology. 2023. doi:10.1093/jpp/rgad049
BibTeX
@article{MahmoudRefaie2023,
author = {Mahmoud Refaie, Marwa Monier and Ahmed Rifaai, Rehab and Bayoumi, Asmaa M A and Shehata, Sayed},
title = {Sacubitril/valsartan cardioprotective effect against cisplatin-induced cardiotoxicity via modulation of VEGF/eNOS and TLR4/TNFα/IL6 signalling pathways},
journal = {Journal of Pharmacy and Pharmacology},
year = {2023},
doi = {10.1093/jpp/rgad049}
}
EUVIMED